Pharmacometabolomics of statin response.

Article Details

Citation

Copy to clipboard

Krauss RM, Zhu H, Kaddurah-Daouk R

Pharmacometabolomics of statin response.

Clin Pharmacol Ther. 2013 Nov;94(5):562-5. doi: 10.1038/clpt.2013.164. Epub 2013 Aug 14.

PubMed ID

23945822 [ View in PubMed

]

Abstract

Statins reduce risk of cardiovascular disease (CVD) by decreasing plasma low-density lipoprotein (LDL) concentrations, as well as reducing inflammation and improving endothelial function. Despite their documented efficacy, there is considerable interindividual variation in effects of statins on CVD biomarkers. In the studies summarized here, we used complementary metabolomics platforms to define global effects of a statin (simvastatin) on metabolism and to identify markers indicative of mechanisms that contribute to variation in plasma LDL response to statin treatment.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Simvastatin	Approved	Tocopherol	decreased	Simvastatin decreases the level of Tocopherol in the blood
Simvastatin	Approved	LaUric acid	decreased	Simvastatin decreases the level of LaUric acid in the blood
Simvastatin	Approved	Glycerol	increased	Simvastatin increases the level of Glycerol in the blood
Simvastatin	Approved	2-hydroxyvaleric acid	decreased	Simvastatin decreases the level of 2-hydroxyvaleric acid in the blood
Simvastatin	Approved	Oxalic acid	decreased	Simvastatin decreases the level of Oxalic acid in the blood
Simvastatin	Approved	Threonine	increased	Simvastatin increases the level of Threonine in the blood
Simvastatin	Approved	Cholesterol	decreased	Simvastatin decreases the level of Cholesterol in the blood